• Explore /
  • Poster
  • / Pralsetinib in patients (pts) with advanced or metastatic <em>RET</em>-altered thyroid cancer (TC): Updated data from the ARROW trial.

Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.

Abstract Video & Slides Poster

Authors

Aaron Scott Mansfield

Aaron Scott Mansfield

Mayo Clinic, Rochester, MN

Aaron Scott Mansfield , Vivek Subbiah , Martin H. Schuler , Viola Weijia Zhu , Julien Hadoux , Marcia S. Brose , Giuseppe Curigliano , Lori J. Wirth , Elena Garralda , Douglas Adkins , Yann Godbert , Myung-Ju Ahn , Philippe Alexandre Cassier , Byoung Chul Cho , Chia-Chi Lin , Hui Zhang , Alena Zalutskaya , Teresa Barata , Astrid Scalori , Matthew H. Taylor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT03037385

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6080)

DOI

10.1200/JCO.2022.40.16_suppl.6080

Abstract #

6080

Poster Bd #

72

Abstract Disclosures

Similar Posters

First Author: Lori J. Wirth

First Author: Matthew H. Taylor

First Author: Giuseppe Curigliano

First Author: Janice Kim